Humanigen Inc (fka HGENQ)

[DonDonDonDon]

these small NIH studies move very slowly. Will they get faster, probably, but Lenz was selected late July 2020!

Currently, there are hundreds of Covid treatment trials in the US and thousands in the world. And they are all competing with each other for patients which is why they are enrolling slowly. Once more doctors/scientists learn about GM-CSF's crucial role in stopping Covid, the handful of studies with anti-GM-CSF drugs should enroll very quickly. And when lenzilumab releases great trial data, this will help other anti-GM-CSF drugs get support instead of hinder them since it confirms the MoA. We are in the infancy of anti-GM-CSF drug treatments, not the finish line. Although, lenzilumab has a huge headstart and will likely get an EUA long before the competition.